Author:
Wang Zehua,Chen Chen,Wang Lei,Jia Yongxu,Qin Yanru
Abstract
Multiple myeloma (MM) is a malignant plasma cell disorder that remains incurable for most patients, as persistent clonal evolution drives new mutations which confer MM high-risk signatures and resistance to standard care. The past two decades have significantly refashioned the therapeutic options for MM, especially adoptive T cell therapy contributing to impressive response rate and clinical efficacy. Despite great promises achieved from chimeric antigen receptor T-cell (CAR-T) therapy, the poor durability and severe toxicity (cytokine release syndrome and neurotoxicity) are still huge challenges. Therefore, relapsed/refractory multiple myeloma (RRMM), characterized by the nature of clinicopathologic and molecular heterogeneity, is frequently associated with poor prognosis. B Cell Maturation Antigen (BCMA) is the most successful target for CAR-T therapy, and other potential targets either for single-target or dual-target CAR-T are actively being studied in numerous clinical trials. Moreover, mechanisms driving resistance or relapse after CAR-T therapy remain uncharacterized, which might refer to T-cell clearance, antigen escape, and immunosuppressive tumor microenvironment. Engineering CAR T-cell to improve both efficacy and safety continues to be a promising area for investigation. In this review, we aim to describe novel tumor-associated neoantigens for MM, summarize the data from current MM CAR-T clinical trials, introduce the mechanism of disease resistance/relapse after CAR-T infusion, highlight innovations capable of enhanced efficacy and reduced toxicity, and provide potential directions to optimize manufacturing processes.
Funder
National Natural Science Foundation of China
Subject
Immunology,Immunology and Allergy
Reference197 articles.
1. [Multiple myeloma - current status in diagnostic testing and therapy];Kehrer;Z fur Orthopadie und Unfallchirurgie,2017
2. Multiple myeloma: Diagnosis and treatment;Michels;Am Family Physician,2017
3. Epidemiology, staging, and management of multiple myeloma;Padala;Med Sci (Basel Switzerland),2021
4. Multiple myeloma;Kumar;Nat Rev Dis Primers,2017
5. The cancer-immunity cycle in multiple myeloma;Casey;ImmunoTargets Ther,2021
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献